Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Emitasvir

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Emitasvir on our secure patient portal to submit your prescription, upload documents and track your approval status.

Emitasvir

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Emitasvir
Generic Name (API): Emitasvir Phosphate
Dosage Form & Strength: 100 mg (0.1 g)
Route: Oral
Drug Class: Direct-acting antiviral, HCV NS5A inhibitor

Manufacturer / Innovator:

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Regulatory Approval:

  • NMPA (China)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Emitasvir Used For?

Emitasvir is a Chinese oral antiviral for adults whose hepatitis C virus is genotype 1 and whose liver has not yet developed cirrhosis. One 100 mg capsule is swallowed each day alongside sofosbuvir, and the pair is continued for 12 weeks. Its marketing licence in China is held by YiChang HEC ChangJiang Pharmaceutical Co., Ltd., part of the HEC (Dongyangguang) group, and Chinese news reports give its brand as 东卫恩 (Dongwei'en).

The National Medical Products Administration (NMPA) of China granted marketing approval in December 2020 as a Class 1 innovative chemical drug, under approval number 国药准字H20200015. The approved use is narrow and specific:

  • Adults with chronic hepatitis C caused by genotype 1 virus
  • Liver without cirrhosis
  • Always given in combination with sofosbuvir tablets, never on its own

A liver specialist confirms the genotype and checks for scarring before deciding whether this course fits. Our hepatology medicines section lists the other imported liver treatments we help with.

How It Works

The capsule contains emitasvir phosphate, an inhibitor of NS5A, a viral protein that hepatitis C relies on for replicating its RNA and packaging fresh copies of itself. Its partner works on NS5B, the polymerase enzyme, so each day the virus is hit at two separate steps of its life cycle. Hitting two targets together is what makes a short, all-oral course possible.

What the Trial Showed

The registration study (NCT03487107) was a single-arm, open-label phase 3 trial at 36 hospitals in mainland China, published in the Journal of Clinical and Translational Hepatology in 2020. It enrolled 362 adults with genotype 1 infection and no cirrhosis (359 genotype 1b, 3 genotype 1a); about one in five had already been through interferon-based therapy.

  • SVR12: 99.7% (361 of 362) tested virus-free three months after their final capsule
  • Prior interferon: all 73 such patients reached SVR12
  • Resistance changes at baseline: 99.2% of patients whose virus already carried NS5A changes still responded
  • Relapse: the infection came back in just two people once treatment had ended

Recommended Dosage

  • Capsule: 100 mg (0.1 g) once daily by mouth
  • Partner: sofosbuvir 400 mg once daily over the same period
  • Duration: 12 weeks, as used in the phase 3 study and listed in the 2022 Chinese hepatitis C guideline
  • Ask your doctor about timing with meals and about any kidney or liver problems before you begin; the Chinese pack leaflet is the reference for these points.

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Part of a two-drug course: this capsule only works with sofosbuvir, so the warnings in the sofosbuvir prescribing information cover the whole 12 weeks as well. Stopping one medicine means the other is stopped too.

  • Hepatitis B can wake up: in people who carry hepatitis B, clearing hepatitis C with direct-acting antivirals has occasionally reactivated it, sometimes with severe liver injury. A blood test for HBsAg and anti-HBc is done first, and anyone positive is watched closely during and after the course.
  • Heart rhythm: the sofosbuvir label warns that a dangerously slow heartbeat can occur when a sofosbuvir-containing regimen is combined with a particular heart-rhythm drug, especially with beta blockers or in advanced liver disease. Show the doctor every heart medicine you take.
  • Blood fats and uric acid: in the trial, treatment-related rises in cholesterol (8.3%), triglycerides (5.2%) and uric acid (4.7%) were the most frequent findings, so routine blood tests are worthwhile.
  • Muscle and pancreas enzymes: creatine phosphokinase went up in 3.9% of patients, lipase in 3.3% and amylase in 2.2%. Unexplained muscle pain or upper belly pain should be reported.
  • People outside the study: the trial left out anyone with cirrhosis, hepatitis B or HIV co-infection, or earlier direct-acting antiviral treatment, so there is little information for these groups.
  • Pregnancy: pregnant women were excluded, and trial patients agreed to effective contraception from the start of treatment until 90 days after it ended. Talk to your doctor before starting if pregnancy or breastfeeding is possible.

Side effects in the phase 3 study (362 patients): any adverse event was recorded in 77.1%, most often upper respiratory infection (14.1%), high cholesterol (13.5%) and high triglycerides (9.7%). About one in three (35.6%) had an event judged related to treatment, mostly grade 1. Sixteen people (4.4%) had a serious event, none considered linked to the medicines. Nobody stopped or paused treatment because of side effects, and no deaths occurred.

How to Access Emitasvir in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Emitasvir to India?

Each import is made in the name of a single patient, applied for by that patient or the treating hospital, under the Indian rules for personal import of unregistered medicines. Keep these papers ready:

  • A prescription from a hepatologist or gastroenterologist covering both capsule and partner tablet for 12 weeks
  • Reports confirming genotype 1, a current HCV RNA viral load, a FibroScan or similar result showing no cirrhosis, and hepatitis B screening
  • The patient's government photo ID

How is the order confirmed?

Only after the prescription and reports have been checked and any import permit required has come through.

Is Emitasvir available in India?

No. CDSCO has not granted it marketing approval, so you will not find it at an Indian chemist. Neither the American FDA nor Europe's EMA has licensed it; China is the only country where it is registered.

Your specialist may ask for it under the Named Patient Program (NPP), the lawful path for importing an unregistered medicine for a single patient. The same HEC group also makes the newer pan-genotypic pairing of netanasvir and encofosbuvir tablets, which we can also arrange on prescription.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is a small-molecule capsule, and we keep and transport it following the storage line printed on the Chinese carton, unopened, using temperature-controlled shipping. At one capsule a day, a full course is 84 capsules; the number of boxes depends on the pack size supplied, which we confirm in the quote. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Being an oral capsule rather than a cold-chain injection, this medicine can be sent to most Indian cities once a liver specialist's prescription and the import papers are complete.

Delhi

Liver hospitals in the capital treat many genotype 1 patients, and dispatch from our base in New Delhi means a short wait once papers are cleared.

Mumbai

A Mumbai hepatologist can email the genotype and FibroScan reports, and we confirm import needs for both medicines in the course.

Bangalore

Patients in Bangalore can choose home delivery or collection at the clinic that will run their week-4 and end-of-treatment tests.

Chennai

Gastroenterology units in Chennai can fix a start date with us so all 84 capsules are in hand before day one.

Hyderabad

For Hyderabad and the rest of Telangana, one complete shipment avoids breaks in the daily dose over 12 weeks.

Kolkata

Families in Kolkata and the eastern states receive a written estimate and expected arrival date before anything is booked.

Pune

Pune patients get a message at each step, from document check to customs clearance to final hand-over.

Ahmedabad

Doctors in Ahmedabad and across Gujarat can begin the request by sharing the prescription and recent HCV RNA result.

Jaipur

People in Jaipur and smaller Rajasthan towns can receive the capsules by courier and avoid a long trip for collection.

Chandigarh

Treating doctors in Chandigarh, Mohali and the hill states can arrange for all 12 weeks of capsules to reach their clinic.

Lucknow

In Lucknow and across Uttar Pradesh, we work with the treating doctor so every document carries the patient's own name.

Kochi

Patients in Kochi and elsewhere in Kerala can receive the sealed cartons at home after the prescription is verified.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 20 November 2026

More Hepatology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP